Association of Serum Magnesium and Blood Pressure in Patients with Hypertensive Crises: A Retrospective Cohort Study

IfeanyiChukwu O. Onor, Pharm.D., BCPS, FNKF
Lashira M. Hill, Pharm.D.
Modupe M. Famodimu, Pharm.D., BCPS
Mallory R. Coleman, Pharm.D.
Carolkim H. Huynh, Pharm.D.
Robbie A. Beyl, Ph.D.
Casey J. Payne, Pharm.D.
Emily K. Johnston, Pharm.D., BCCCP
John I. Okogbaa, Pharm.D., BCPS
Christopher J. Gillard, Pharm.D., BCPS
Daniel F. Sarpong, Ph.D.
Amne Borghol, Pharm.D., BCPS
Samuel C. Okpechi, B.S.
Ifeyinwa Norbert, M.D.
Shane E. Sanne, D.O.
Shane G. Guillory, M.D.
CardioRenal Research Group (CRRG)
1 CardioRenal Research Group (CRRG), College of Pharmacy, Xavier University of Louisiana, 1 Drexel Drive, New Orleans, LA 70125
2 Department of Medicine, Louisiana State University Health Sciences Center School of Medicine, 1542 Tulane Avenue, New Orleans, LA 70112
3 Department of Pharmacy, University Medical Center New Orleans, 2000 Canal Street, New Orleans, LA 70112
4 Pennington Biomedical Research Center, 6400 Perkins Road, Baton Rouge, LA 70808
5 Center for Minority Health and Health Disparities Research and Education, College of Pharmacy, Xavier University of Louisiana, 1 Drexel Drive, New Orleans, LA 70125, USA
6 Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, 1901 Perdido Street, New Orleans, LA 70112

**Corresponding Author:** IfeanyiChukwu O. Onor, Pharm.D., BCPS, FNKF
Abstract

Background: The role of magnesium in blood pressure has been studied among hypertensive patients, however, no study has explored the role of magnesium in hypertensive crises. The primary objective of this study is to evaluate the relationship between serum magnesium and blood pressure in patients with hypertensive crises.

Methods: This study is a single-center, retrospective, chart review, cohort study of patients with hypertensive crises. Patients were included in the study cohort if they were eighteen years of age or older with an international classification disease ninth revision (ICD-9) code of 401.9 (hypertensive crises: emergency or urgency) and a documented magnesium level on their electronic medical record. The primary outcome of the study was to assess the correlation between serum magnesium on blood pressure (systolic blood pressure and diastolic blood pressure) in patients with hypertensive crises. The secondary outcomes were to assess the association between serum calcium, corrected calcium, and serum potassium on blood pressure in patients with hypertensive crises and to determine the effects of covariates in modulating the relationship between serum magnesium and blood pressure.

Results: Two hundred and ninety-three patients were included in the study. The primary outcome result showed that serum magnesium was positively correlated with systolic blood pressure ($r=0.143$, $p=0.014$), but not diastolic blood pressure. Serum calcium was also found to be positively correlated with systolic blood pressure, but not diastolic blood pressure. After adjusting for covariates in the solution for fixed effects analysis, serum magnesium, serum calcium, corrected calcium, and use of home proton pump inhibitors were correlated with systolic blood pressure at crises; while age, serum calcium, and corrected calcium were significantly correlated with diastolic blood pressure at crises.
Conclusion: This study found a significant positive association between magnesium and systolic blood pressure, but not diastolic blood pressure among patients with hypertensive crises. This positive association of serum magnesium with systolic blood pressure was maintained after adjusting for covariates. This study findings suggests a potential role of magnesium in blood pressure among patients with hypertensive crises. Future studies should evaluate the role of serum magnesium modifying therapies in controlling blood pressure in patients with hypertensive crises.

Keywords: Magnesium, Blood Pressure, Hypertensive Crises
Introduction

Magnesium is the second most abundant intracellular cation after potassium and the fourth most abundant cation in the body (1–3). In adult humans, total body magnesium store is approximately 24 grams with 99% existing intracellularly [bone (53%), muscle (27%), and soft tissue (19%)] and 1% existing in the extracellular space (serum and erythrocytes) (1,2). Normal total serum concentration is in the range of 1.7–2.6 mg/dL (0.7–1.1 mmol/L) (1). This serum magnesium range represents approximately 0.3% of total body magnesium and may not accurately reflect the total magnesium status (2,4). Ten percent of serum magnesium is complexed to serum anions, thirty percent of serum magnesium is albumin-bound, and sixty percent of serum magnesium exists in the ionized, free physiologically active form (1). Serum magnesium homeostasis is regulated by the interplay between intestinal transport, bone transport, and renal exchange (1). Magnesium is involved in a plethora of physiologic processes in the body namely: intracellular signaling, serving as a cofactor for DNA & protein synthesis, oxidative phosphorylation, cardiac excitability, vasomotor tone, blood pressure regulation, neuromuscular transmission, and bone formation (1–3).

Hypertension is a condition characterized by elevation in the systolic blood pressure (SBP) and/or diastolic blood pressure (DBP) (5,6). Clinical practice guidelines define hypertension using different cutpoints as either SBP ≥ 130 mmHg and/or DBP ≥ 80 mmHg (7) or SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg (8,9). The global prevalence of hypertension in adults is between 30% - 45%; with a global age-adjusted prevalence of 24% and 20% in men and women, respectively (9). The prevalence of hypertension among US adults depends on the clinical practice guideline cutpoints to categorize blood pressure; with an overall prevalence of hypertension among US adults between 32% - 46% and age-sex adjusted prevalence range of 31% - 48% for men and 32% - 43% in women (7,8). Hypertension remains a leading risk factor for cardiovascular diseases (hemorrhagic stroke, ischemic stroke, myocardial
infarction, angina, heart failure, peripheral artery disease, and aortic aneurysm), end-stage renal
disease, death, and disability (5–10). Hypertensive crises is defined as SBP greater than 180 mmHg
and/or DBP greater than 120 mmHg (7,8). Hypertensive crises can be further classified into:
hypertensive urgency (when there is no evidence of target organ damage) and hypertensive emergency
(when there is evidence of target organ damage) (7,8). Although hypertensive urgency reflects a marked
elevation in blood pressure, it can be managed by increasing or optimizing the dose of oral
antihypertensive agents. Hypertensive emergency, however, is characterized with target organ damage
and is associated with a 1-year mortality rate of > 79%; thus necessitating swift blood pressure reduction
with intravenous antihypertensive agents to prevent sustained deterioration of target organ damage
(7,8). The principal focus of our study is to examine the role of magnesium on SBP and DBP in
hypertensive crises anchored by background evidence from studies evaluating the role of magnesium in
hypertension.

Multiple clinical trials have shown, albeit inconsistently, that magnesium deficiency (serum and/or
tissue) occurs to some degree in hypertensive subjects; with low magnesium levels linked to a significant
undesirable effect on blood pressure (11–16). Although magnesium has been postulated to modulate
blood pressure regulation, the precise mechanism of altered magnesium metabolism in hypertensive
individuals remain unclear (11). The prevalent postulated mechanism of the effect of magnesium on
blood pressure is that magnesium acts as a natural calcium antagonist on most types of calcium
channels in vascular smooth muscles, thus reducing arterial blood pressure through lowering of
peripheral and cerebral vascular resistance (11). More specifically, the activity of magnesium as a
calcium antagonist produces endothelial dependent vasodilation and reduction of blood pressure
through increases of extracellular magnesium and reduction of calcium influx (4,11,17,18). Magnesium
has also been shown to produce vasodilation by increasing prostaglandin E – a vasodilator and platelet
inhibitor (17,18). Magnesium is also an essential cofactor for delta-6-desaturase enzyme which converts linoleic acid to gamma linolenic acid, a precursor to prostaglandin E (17,18). Additionally, a strong interaction has been found between magnesium and other electrolytes (potassium, calcium, and sodium) in blood pressure reduction; with reduction of intracellular sodium and calcium, and increases in intracellular magnesium and potassium shown to improve blood pressure (17,18).

Several observational clinical studies and a meta-analysis have evaluated the relationship between serum magnesium and blood pressure in patients with and without hypertension (12,14,25,15,16,19–24); however, no published study to our knowledge has evaluated serum magnesium and blood pressure relationship among patients with hypertensive crises. The available published studies performed tests of association (correlation, odds ratio, risk ratios, and hazard ratios) between magnesium and either blood pressure or hypertension (12,14,25,15,16,19–24). Among the ten studies that performed a test of association between serum magnesium and either blood pressure or hypertension, six studies found a significant negative association (14–16,20,21,24), three studies found no significant relationship (12,19,23), and one study found a significant positive correlation between serum magnesium and blood pressure in women only (25). The meta-analysis by Han et al. found no significant association between serum magnesium and blood pressure, although there was a trend towards negative association between serum magnesium and blood pressure (Risk Ratio (RR) = 0.91, 95% CI: 0.80 – 1.02) (22). Collectively, these studies have revealed conflicting evidence on the relationship between serum magnesium levels and either blood pressure or hypertension; with some studies showing negative association (14–16,20,21,24), and others showing either no association (12,19,22,23,25) or a positive association (25). Similarly, the effect of magnesium supplementation on blood pressure has been studied extensively. Nine out of the ten studies (clinical trials, Cochrane Review and meta-analyses) reviewed showed mostly positive association/effect of magnesium supplementation...
in lowering SBP, DBP, or both (22,26–33); and only one study found no significant effect of magnesium supplementation on blood pressure (34). This prevailing positive effect of magnesium supplementation in lowering blood pressure proved compelling and served as the foundational rationale for our study evaluating whether serum magnesium is a factor that contributes to the dysregulated high blood pressure seen in patients with hypertensive crises. We hypothesized that low serum magnesium will be significantly associated with blood pressure (SBP and DBP) in patients with hypertensive crises.

The primary objective of this study is to evaluate the correlation between serum magnesium and blood pressure (SBP and DBP) in hypertensive crises. Secondary objectives were to evaluate the association between serum calcium, corrected calcium, and serum potassium on blood pressure in patients with hypertensive crises, and to determine the effects of covariates [age, sex, race, body mass index (BMI), history of diabetes mellitus, use of proton pump inhibitors at home, use of blood pressure medications at home or hospital, use of oral magnesium at home, use of intravenous magnesium at hospital, serum calcium at crises, corrected calcium at crises, and serum potassium at crises] in modulating the relationship between serum magnesium and blood pressure.
Study Design and Methods:

This study is a single-center, retrospective, chart review, cohort study conducted at the Interim Louisiana State University Hospital (ILH) – New Orleans, Louisiana. The study cohort data was reviewed from patients who were admitted to ILH with hypertensive crises during a 2-year period from July 2012 to July 2014. This study was approved by the Xavier University of Louisiana Institutional Review Board (IRB) and ILH Research Review Committee (RRC).

Patients who were eighteen years of age or older with an international classification disease ninth revision (ICD-9) code of 401.9 (hypertensive crises: emergency or urgency) and a documented magnesium level on their electronic medical record (during the hypertensive crises hospital admission) were included in the study cohort. Hypertensive crises was defined as systolic blood pressure (SBP) greater than 180 mmHg and/or diastolic blood pressure (DBP) greater than 120 mmHg. Patients identified as having hypertensive crises based on ICD-9 codes were confirmed to have either systolic blood pressure (SBP) greater than 180 mmHg and/or diastolic blood pressure (DBP) greater than 120 mmHg. Hypertensive crises was further categorized as either hypertensive urgency (absence of acute or on-going target organ damage) or hypertensive emergency (presence of acute or on-going target-organ damage). Target organ damage by system included neurologic (hypertensive encephalopathy, intracranial hemorrhage, acute ischemic stroke), cardiac (acute myocardial infarction, acute left ventricular failure, unstable angina, dissecting aortic aneurysm), and renal (acute kidney injury). All diagnoses of target organ damage were confirmed with both the physician diagnosis documented on the patients’ problem list and clinical findings (laboratory results, imaging, signs, and symptoms) made on the patients. Hypertensive encephalopathy diagnosis was verified based on physical exam findings of headache and altered level of consciousness. Diagnosis of intracranial hemorrhage and acute ischemic stroke was confirmed using a computed tomography (CT) scan or magnetic resonance imaging of the
head with or without contrast, and was performed on patients with neurologic symptoms, which includes change in mental status or focal neurologic signs indicative of cerebrovascular accident or hemorrhage. Unstable angina diagnosis was made clinically and confirmed with documented new or sudden chest pain, while myocardial infarction diagnosis was confirmed with elevated serum troponin levels and electrocardiogram (EKG) findings. Acute left ventricular failure was diagnosed with echocardiographic findings of a decreased ejection fraction less than 40% as well as physical exam findings of elevated jugular venous pressure (distension), crackles, or edema. Diagnosis of dissecting aortic aneurysm was confirmed from imaging studies revealing wide mediastinum on chest x-ray and/or chest CT scan with or without contrast. Acute kidney injury was defined as a serum creatinine (SCr) greater than 2 mg/dL, which is new onset in absence of prior renal disease and/or increase in SCr of 0.5 mg/dL or greater.

Patients were excluded if they had conditions interfering with serum magnesium levels such as: chronic kidney disease (CKD) stages 4 and 5, end-stage renal disease (ESRD), hepatic cirrhosis, pheochromocytoma, chronic diarrhea, and hyperaldosteronism. Additionally, patients who received inotropes or vasopressors (including epinephrine, norepinephrine, dopamine, phenylephrine, vasopressin, dobutamine, or milrinone) during the hospital encounter were excluded from the study.

All patient data was obtained from ILH’s electronic medical record. The following demographic data was collected: age, sex, race, body mass index (BMI), and history of diabetes mellitus. Outcome variables collected included serum magnesium (mg/dL), serum calcium (mg/dL), serum potassium (mEq/L), SBP (mmHg), and DBP (mmHg). All outcome variables were collected at a time closest to the first documented hypertensive crises’ blood pressure during the hospital encounter and is denoted as “at crises”. Additionally, maximum and minimum values of SBP and DBP were recorded within 24-hours of
the first recorded hypertensive crises' blood pressure. Corrected calcium (mg/dL) was calculated using
the formula: corrected calcium = patient’s measured serum calcium in mg/dL + (0.8 * (4 gm/dL –
patient’s measured albumin in gm/dL)). The corrected calcium was only calculated for patients whose
serum albumin was less than 4 gm/dL. Additional predictor variables collected include: home and
hospital use of blood pressure medications [inclusive of all blood pressure medication classes (for
example: calcium channel blockers) grouped in the electronic health record], at home use of proton
pump inhibitors, home use of oral magnesium, hospital use of intravenous magnesium, and albumin
levels (gm/dL).

Outcomes
The primary outcome of the study was to assess the correlation between serum magnesium on blood
pressure (SBP and DBP) in patients with hypertensive crises. The secondary outcomes of this study were
to evaluate the association between serum calcium, corrected calcium, and serum potassium on blood
pressure in patients with hypertensive crises, and to determine the effects of covariates (age, sex, race,
BMI, history of diabetes mellitus, use of proton pump inhibitors at home, use of blood pressure
medications at home or hospital, use of oral magnesium at home, use of intravenous magnesium at
hospital, serum calcium at crises, corrected calcium at crises, and serum potassium at crises) in
modulating the relationship between serum magnesium and blood pressure. An additional exploratory
outcome was to perform correlation analyses of serum magnesium, serum calcium, corrected calcium,
and serum potassium on the two independent variables: SBP and DBP measured at different time
points.
We performed a power analysis based on findings of our primary outcome variables (serum magnesium, SBP, and DBP) from prior studies. Based on these studies, we estimate that the $R^2$ (coefficient of determination) for the linear regression between serum magnesium and either SBP or DBP will range between 0.06 – 0.56. Our power analysis revealed that the target sample size for this study will range between 140 – 180 subjects, to give us a power of 0.80 at a significance level of 5%.

Descriptive statistical analysis was performed on demographic characteristics. Measures of central tendency were obtained for continuous measures and frequency distribution for categorical measures. Simple linear regression was performed to assess the correlation ($r$) and coefficient of determination ($R^2$) between serum magnesium, serum calcium, corrected calcium, and serum potassium on blood pressure (SBP and DBP) in patients with hypertensive crises. A linear model analysis was performed to assess effects of serum magnesium (and other electrolytes) on blood pressure (SBP and DBP) at the time of hypertensive crises while adjusting for covariates. Statistical analyses were performed using SAS® version 9.4. An alpha value of less than 0.05 was considered statistically significant.
Results:

Figure 1. Flow chart of inclusion to study cohort.
## Table 1. Baseline Characteristics (N = 293)

| Demographic variables                    | Values                                    |
|------------------------------------------|-------------------------------------------|
| Age [Mean ± SD years; (range)]           | 56.70 ± 12.86 (19 – 97)                  |
| Sex                                      |                                           |
| Male:                                    | 146 (49.83%)                              |
| Female:                                  | 147 (50.17%)                              |
| Race                                     |                                           |
| White:                                   | 62 (21.16%)                               |
| Black/African-American:                  | 213 (72.7%)                               |
| Asian:                                   | 3 (1.02%)                                 |
| Other:                                   | 15 (5.12%)                                |
| Hypertensive Crises Diagnosis            |                                           |
| Hypertensive Urgency:                    | 220 (75.09%)                              |
| Hypertensive Emergency:                  | 73 (24.91%)                               |
| History of Diabetes mellitus             |                                           |
| Diabetic:                                | 102 (34.81%)                              |
| Non-diabetic:                            | 191 (65.19%)                              |
| Body Mass Index (BMI) [Mean ± SD kg/m²; (range)] (N=290) | 30.59 ± 9.33 (16.70 – 69.10)             |
| Use of Home Proton Pump Inhibitors (N=259) | 53 (20.46%)                              |
| Use of Home Blood Pressure Medications (N=264) | 227 (85.98%)                    |
| Use of Hospital Blood Pressure Medications | 283 (96.59%)                              |
| Use of Home Magnesium (Oral) (N=292)     | 31 (10.62%)                               |
| Use of Hospital Magnesium (Intravenous) (N=292) | 95 (32.53%)                              |
| Serum Magnesium at Crises (Mean ± SD mg/dL; (range)] | 1.93 ± 0.36 (0.80 – 3.90)                |
| Serum Calcium at Crises (Mean ± SD mg/dL; (range)] | 8.92 ± 0.92 (0.80 – 13.10)               |
| Corrected Calcium at Crises (Mean ± SD mg/dL; (range)] (N=207) | 9.33 ± 0.90 (1.12 – 13.34)              |
| Variable                          | Mean ± SD mg/dL; (range) |
|----------------------------------|--------------------------|
| Serum Potassium at Crises        | 3.92 ± 0.64 (1.40 – 6.30) |
| Systolic Blood Pressure          | 194.2 ± 21.31 (136 – 265) |
| Diastolic Blood Pressure         | 113.7 ± 21.38 (53 – 180)  |

**Table 2.** Association of serum magnesium (other electrolytes) and SBP at Crises or DBP at Crises

**Relationship between magnesium and SBP at Crises or DBP at Crises (N=293)**

| Variables              | r    | R²   | P-value |
|------------------------|------|------|---------|
| Serum Magnesium        | 0.143| 0.020| 0.014   |
| Serum Calcium          | 0.187| 0.035| 0.001   |
| Corrected Calcium (N=207) | 0.049| 0.002| 0.482   |
| Serum Potassium        | -0.076| 0.006| 0.195   |

| Variables              | r    | R²   | P-value |
|------------------------|------|------|---------|
| Serum Magnesium        | 0.033| 0.001| 0.570   |
| Serum Calcium          | 0.090| 0.008| 0.124   |
| Corrected Calcium (N=207) | -0.011| 0.000| 0.873   |
| Serum Potassium        | -0.113| 0.013| 0.053   |
Table 3. Association of serum magnesium and SBP at Crises or DBP at Crises using linear models (adjusted for covariates)

| Relationship between serum magnesium and SBP at Crises or DBP at Crises (N=293) |
|--------------------------------------------------|-----------------|----------------|
| Variables                                        | β ± SE           | P-value        |
|--------------------------------------------------|-----------------|----------------|
| **SBP at Crises**                                |                 |                |
| Serum Magnesium                                  | 11.25 ± 4.67    | 0.017          |
| **DBP at Crises**                                |                 |                |
| Serum Magnesium                                  | 2.56 ± 4.93     | 0.6031         |

Adjusted for covariates – Age, sex, race, history of diabetes, BMI, use of proton pump inhibitors at home, use of blood pressure medications at home or hospital, use of oral magnesium at home, use of intravenous magnesium at hospital, serum calcium at crises, corrected calcium at crises, and serum potassium at crises.
**Table 4.** Best Predictor Variables on SBP at Crises using linear models (adjusted for covariates)

| Predictor Variables                  | SBP at Crises | P-value |
|--------------------------------------|---------------|---------|
| Serum Magnesium                      | 11.25 ± 4.67  | 0.017   |
| Serum Calcium                        | 9.50 ± 3.37   | 0.006   |
| Corrected Calcium                    | -7.82 ± 3.54  | 0.029   |
| Use of Home Proton Pump Inhibitors   | 9.13 ± 3.85   | 0.019   |

Covariates in the Mixed Model – Age, sex, race, history of diabetes, BMI, use of proton pump inhibitors at home, use of blood pressure medications at home or hospital, use of oral magnesium at home, use of intravenous magnesium at hospital, serum magnesium at crises, serum calcium at crises, corrected calcium at crises, and serum potassium at crises.

Alpha of < 0.05 defined as significant for best predictor variables.
**Table 5.** Best Predictor Variables on DBP at Crises using linear models (adjusted for covariates)

| Predictor Variables              | DBP at Crises     |
|----------------------------------|-------------------|
|                                  | β ± SE            | P-value       |
| Serum Calcium                    | 16.21 ± 3.56      | <0.0001       |
| Corrected Calcium                | -14.12 ± 3.74     | 0.0002        |
| Age                              | -0.53 ± 0.12      | <0.0001       |

Covariates in the Mixed Model – Age, sex, race, history of diabetes, BMI, use of proton pump inhibitors at home, use of blood pressure medications at home or hospital, use of oral magnesium at home, use of intravenous magnesium at hospital, serum magnesium at crises, serum calcium at crises, corrected calcium at crises, and serum potassium at crises.

Alpha of < 0.05 defined as significant for best predictor variables.
| Variables               | Serum Magnesium at Crises (N=293) |
|-------------------------|-----------------------------------|
|                         | r       | R²      | P-value |
| SBP at Crises           | 0.143   | 0.020   | 0.014   |
| SBP Maximum (24-hr)     | 0.104   | 0.011   | 0.074   |
| SBP Minimum (24-hr)     | -0.034  | 0.001   | 0.563   |
| DBP at Crises           | 0.033   | 0.001   | 0.570   |
| DBP Maximum (24-hr)     | 0.041   | 0.002   | 0.480   |
| DBP Minimum (24-hr)     | 0.021   | 0.000   | 0.726   |

Table 6. Correlation of Serum Magnesium at Crises on SBP and DBP at different time points

| Variables               | Serum Calcium at Crises (N=293) |
|-------------------------|---------------------------------|
|                         | r       | R²      | P-value |
| SBP at Crises           | 0.187   | 0.035   | 0.001   |
| SBP Maximum (24-hr)     | 0.134   | 0.018   | 0.022   |
| SBP Minimum (24-hr)     | 0.237   | 0.056   | <0.0001 |
| DBP at Crises           | 0.090   | 0.008   | 0.124   |
| DBP Maximum (24-hr)     | 0.121   | 0.015   | 0.038   |
| DBP Minimum (24-hr)     | 0.183   | 0.033   | 0.002   |

Table 7. Correlation of Serum Calcium at Crises on SBP and DBP at different time points
Table 8. Effect of Corrected Calcium at Crises on SBP and DBP at different time points

| Variables                  | Corrected Calcium at Crises (N=207) |
|----------------------------|-------------------------------------|
|                            | r        | R²       | P-value |
| SBP at Crises              | 0.049    | 0.002    | 0.482   |
| SBP Maximum (24-hr)        | -0.028   | 0.001    | 0.690   |
| SBP Minimum (24-hr)        | 0.256    | 0.066    | 0.0002  |
| DBP at Crises              | -0.011   | 0.000    | 0.873   |
| DBP Maximum (24-hr)        | -0.000   | 0.000    | 0.996   |
| DBP Minimum (24-hr)        | 0.177    | 0.031    | 0.011   |

Table 9. Effect of Serum Potassium at Crises on SBP and DBP at different time points

| Variables                  | Serum Potassium at Crises |
|----------------------------|----------------------------|
|                            | r        | R²       | P-value |
| SBP at Crises              | -0.076   | 0.006    | 0.195   |
| SBP Maximum (24-hr)        | -0.074   | 0.005    | 0.209   |
| SBP Minimum (24-hr)        | -0.130   | 0.017    | 0.026   |
| DBP at Crises              | -0.113   | 0.013    | 0.053   |
| DBP Maximum (24-hr)        | -0.065   | 0.004    | 0.265   |
| DBP Minimum (24-hr)        | -0.175   | 0.031    | 0.003   |
Eight-hundred and thirty-seven patients who had a serum magnesium level and an ICD-9 code of 401.9 or a diagnosis of hypertensive crises, hypertensive urgency, and hypertensive emergency were identified from ILH’s electronic medical record (Figure 1). 544 patients were excluded after applying the study exclusion criteria and 293 patients were included in the statistical analysis (Figure 1). Baseline demographics are presented in table 1. The majority of patients were African Americans (72.7%) and the mean age of patients in the study was 56.7 years. Hypertensive urgency (75.1%) was greater in prevalence than hypertensive emergency (24.9%) among all hypertensive crises diagnosis. Nearly 35% of patients had diabetes mellitus and the average BMI of the study population was 30.6 kg/m².

The primary outcome result is displayed on table 2 and showed that serum magnesium was positively correlated (r = 0.143, p-value = 0.014) with SBP at crises, but not DBP at crises. The coefficient of determination (R²) reveals that 2% of the variability in SBP at crises can be attributed to serum magnesium. Beside serum magnesium, serum calcium was the only additional electrolyte significantly correlated with SBP at crises. Serum calcium was positively correlated with SBP at crises, with 3.5% of the variability in SBP at crises attributable to serum calcium. When evaluating DBP at crises, no electrolyte was significantly correlated with DBP at crises; however, serum potassium showed a slight trend towards negative correlation with DBP at crises.

Table 3 assessed the relationship with serum magnesium and both SBP and DBP at crises when adjusting for covariates. The results showed that as serum magnesium increases by 1 mg/dL, SBP at crises increases 11.25 mmHg after adjusting for covariates in the model (p-value = 0.017). Although a significant association was found with serum magnesium and SBP at crises after adjusting for covariates, no significant association was found with serum magnesium and DBP at crises after adjusting for covariates in the model.
Variables that significantly predicted SBP at time of hypertensive crises was assessed using a linear model (adjusted for covariates) and the results are displayed on table 4. When adjusting for covariates, serum magnesium, serum calcium, corrected calcium, and the use of proton pump inhibitors independently emerged as the best variables that predicted SBP at crises, with all showing a positive relationship with SBP at crises except for corrected calcium level showing a negative relationship with SBP at crises. Similarly, table 5 displays the variables that best predicted DBP at time of hypertensive crises using a linear model (adjusted for covariates). In the model, after adjusting for covariates, serum calcium, corrected calcium, and age independently emerged as best variables that significantly predicted DBP at crises. Serum calcium positively predicted DBP at crises in the model, while corrected calcium and age negatively predicted DBP at crises in the model.

Tables 6 through 9 display a result of the correlation matrix analyses of serum magnesium, serum calcium, corrected calcium, and serum potassium on the two independent variables: SBP and DBP measured at different time points. Table 6 showed that serum magnesium was significantly correlated only with SBP at time of crises and the maximum SBP measured within 24-hours of the first hypertensive crises diagnosis. Results displayed on table 7 showed that serum calcium was significantly correlated with SBP and DBP measured at different time points, with the exception of DBP measured at time of crises not showing significant correlation with serum calcium. Corrected calcium results displayed on table 8 revealed that corrected calcium was only significantly correlated with minimum SBP and minimum DBP measured within 24-hours of the first hypertensive crises diagnosis. Lastly, serum potassium was only significantly correlated (negative correlation) with minimum SBP and minimum DBP measured within 24-hours of the first hypertensive crises diagnosis.

Discussion
This study contributes much new knowledge on the role of magnesium in patients with hypertensive crises – a population where the role of magnesium has been sparsely evaluated. The primary outcome of our study evaluated the relationship between magnesium and blood pressure (SBP and DBP) in patients with hypertensive crises.

Using correlation analysis (table 2) and linear regression analysis (table 3), our study found a significant positive correlation between serum magnesium and SBP at crises, but no significant relationship was found between serum magnesium and DBP at crises. This finding of positive correlation between serum magnesium and SBP in our study conflicts with majority of studies that assessed serum magnesium and SBP which have predominantly shown significant negative correlation (12,14–16,21,24,25). Among the seven studies that evaluated the linear relationship (correlation coefficient) between magnesium and either SBP or DBP (12,14–16,21,24,25), majority of these studies (N = 5 out of 7, 71.4%) showed negative relationship between serum magnesium and SBP (14–16,21,24). One of the studies showed no significant relationship between serum magnesium and SBP (12), while one study by Rinner et al. approximated our study finding and revealed a positive relationship between serum magnesium and SBP in women, but not in men (25). With respect to the relationship between serum magnesium and DBP, majority of the studies (N = 4 out of 7, 57%) have shown non-significant relationship which is consistent with our study findings (12,14,24,25). However, three studies found negative correlation between serum magnesium and DBP which contradicts our study results (15,16,21). Our study finding therefore is consistent with most of the available literature showing no strong relationship between serum magnesium and DBP; however our study finding conflicts with the predominant negative linear relationship observed between serum magnesium and SBP in studies. Altogether, our study’s detection of a significant positive association between serum magnesium and SBP in patients with hypertensive crises suggests that serum magnesium may play an important role in the dysregulated blood pressure
seen in patients with hypertensive crises. It is plausible to consider that our study may have had
disparate results from the literature due to potential sources of error from selection bias and
confounding variables.

Among the additional electrolytes (calcium, corrected calcium, and potassium) that we assessed for a
relationship with blood pressure, we found that serum calcium showed significant positive correlation to
SBP at crises, but not DBP at crises. After adjusting for covariates (tables 4 and 5), we found positive
relationship between serum calcium and both SBP and DBP at crises. Similar to our study finding, the
positive association of serum calcium to both SBP and DBP has been reported in several studies that
evaluated the linear relationship between serum calcium and blood pressure (16,35–39). It is important
to reinforce that our study found a relationship between serum calcium and both SBP and DBP at crises
after adjusting for covariates; however the correlation analysis without adjustment for covariates
showed significant positive correlation between serum calcium for SBP at crises, but not DBP at crises.
Corrected calcium was not significantly correlated to either SBP or DBP at crises. In the exploratory
results, we found that corrected calcium was positively associated with both minimum SBP and DBP
within 24-hour of hypertensive crises. The data with corrected calcium should be interpreted cautiously
given that we did not include 86 missing data among patients who did not have serum albumin less than
4 gm/dL. Potassium was also not significantly correlated to either SBP or DBP at crises, although there
was a trend towards a negative correlation between potassium and DBP at crises. This finding is
inconsistent with prior studies which have predominantly shown a negative correlation between serum
potassium and both SBP and DBP (25,40–42). In the exploratory results (tables 6 – 9), we found that
serum potassium was negatively associated with both minimum SBP and DBP within 24-hour of
hypertensive crises. Calcium and potassium were measured because of strong linkages of these
electrolytes with blood pressure, especially in concert with magnesium (7,13,15–18,25).
The strengths of our study include our use of statistical tests that explored association between variables, the pilot nature of our study, and the attainment of our study's desired sample size. We performed regression analysis to examine the association between magnesium (and other electrolytes) and blood pressure in hypertensive crises. Findings from the regression analysis provide us useful information on the relationship between electrolytes and variables. This study is also a pilot/exploratory study and is thus a hypothesis generating study and can provide population estimates to help determine the appropriate sample size to study the effect of magnesium on hypertensive crises in future studies.

Lastly, our study reached and exceeded our desired sample size for the study which decreased the probability of type II errors and improved the probability to detect significant differences that may exist in the true population of patients from which our sample population was obtained.

Our study has several limitations which impact the internal and external validity of our study. First, this study is a single-center study and as such limits the generalizability of our study to patients across institutions. The findings from this single-center study should be extrapolated cautiously to individual patients and patient populations with hypertensive crises. This study was a retrospective study which introduces variability on the time when variables were available; since variables available from the electronic medical record were not collected uniformly at specific times as would be the case in a prospective study. Our study was also a non-interventional/non-experimental study which impacts the internal validity and excludes our study from the ability to assess causation. Our study was not a randomized study and confounding variables may have effect on our study results. Lastly, our study may be susceptible to selection bias as a source of error due to the study inclusion/exclusion criteria and the unique demographic distribution of the study patients at our hospital compared to our study's broad target population of patients with hypertensive crises. Another important study limitation is that
magnesium is predominantly an intracellular cation, thus, the serum magnesium obtained from the electronic hospital record may not be a good reflection of patients’ magnesium stores. (1, 2)

Conclusion

This study found a significant positive association between magnesium and systolic blood pressure, but not diastolic blood pressure among patients with hypertensive crises. This positive association of serum magnesium with systolic blood pressure was maintained after adjusting for covariates. This study findings suggests a potential role of magnesium in blood pressure among patients with hypertensive crises. Large sample experimental studies are needed to evaluate the role of serum magnesium modifying therapies in controlling blood pressure in patients with hypertensive crises. Future studies should also evaluate the role of serum calcium modifying therapies in blood pressure control in patients with hypertensive crises.

List of Abbreviations:

SBP, Systolic blood pressure
DBP, Diastolic blood pressure
ILH, Interim Louisiana State University Hospital
IRB, Institutional Review Board (IRB)
RRC, Research Review Committee
ICD-9, International classification disease ninth revision
CT, Computed Tomography
EKG, Electrocardiogram
Scr, Serum creatinine
CKD, Chronic kidney disease
ESRD, End-stage renal disease
BMI, Body Mass Index
r, Correlation
$R^2$, Coefficient of determination

Acknowledgement
We thank the Interim Louisiana State University Hospital for allowing us to conduct this retrospective study on their patient population.

Funding
This study was supported in part by several grants: RCMI – NIH/NIMHD5G12MD007595 and NIMHD 2U54MD007595-11 from the National Institute of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), and Research Centers in Minority Institutions Program (RCMI); Center for Minority Health and Health Disparities Research and Education – 5 S21 MD 000100-12 from the National Institute on Minority Health and Health Disparities (NIMHD); LaCATS – 1 U54 GM104940 and 2U54GM104940-02 from the National Institute of General Medical Sciences of the National Institutes of Health, which funds the Louisiana Clinical and Translational Science Center (LaCATS); Xavier Center of Excellence - HRSA D34HP00006 from the Health Resources and Service Administration of the Department of Health and Human Services (DHHS); and Title III – Center for Undergraduate Research (CUR) via U.S. Department of Education – Title III, Part B Program.

Authors’ contributions
Research idea and study design: IOO, JIO, CJG, DFS; data acquisition: LMH, MMF, MRC, CHH, CJP, EKJ; data analysis/interpretation: IOO, LMH, MMF, MRC, CHH, CJP, EKJ RAB, DFS, JIO, CJG, AB, SCO, IN, SES,
Each author contributed important intellectual content during manuscript drafting or revision, accepts personal accountability for the author’s own contributions, and agrees to ensure that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved. The author(s) read and approved the final manuscript.

**Ethics approval and consent to participate**

This study was approved by the Xavier University of Louisiana Institutional Review Board (IRB) and ILH Research Review Committee (RRC). All methods were carried out in accordance with relevant guidelines and regulations. This study was a retrospective, chart-review, non-interventional study and was granted a waiver of informed consent by the Xavier University of Louisiana Institutional Review Board (IRB) and ILH Research Review Committee (RRC).

**Consent for publication**

Not applicable.

**Competing interests**

The authors have no financial disclosures
1. Blaine J, Chonchol M, Levi M. Renal control of calcium, phosphate, and magnesium homeostasis. Clin J Am Soc Nephrol. 2015;10(7):1257–72.

2. Fawcett WJ, Haxby EJ, Male DA. Magnesium: Physiology and pharmacology. Br J Anaesthesia [Internet]. 1999;83(2):302–20. Available from: http://dx.doi.org/10.1093/bja/83.2.302

3. Champagne CM. Magnesium in hypertension, cardiovascular disease, metabolic syndrome, and other conditions: A review. Nutr Clin Pract. 2008;23(2):142–51.

4. Kupetsky-Rincon EA, Uitto J. Magnesium: Novel applications in cardiovascular disease - A review of the literature. Ann Nutr Metab. 2012;61(2):102–10.

5. Solomon CG, Taler SJ. Initial treatment of hypertension. N Engl J Med. 2018;378(7):636–44.

6. Oparil S, Acelajado MC, Bakris GL, Berlowitz DR, Cifková R, Dominiczak AF, et al. Hypertension. Nat Rev Dis Prim. 2018;4.

7. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Pr. J Am Coll Cardiol. 2018;71(19):e127–248.

8. National High Blood Pressure Education Program. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. [Internet]. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda (MD): National Heart, Lung, and Blood Institute (US); 2004 [cited 2020 Mar 19]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK9630/

9. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH
Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J [Internet]. 2018 Aug 25;39(33):3021–104. Available from: https://doi.org/10.1093/eurheartj/ehy339

10. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol [Internet]. 2020;1975. Available from: http://dx.doi.org/10.1038/s41581-019-0244-2

11. Geiger H, Wanner C. Magnesium in disease. CKJ Clin Kidney J. 2012;5(SUPPL. 1).

12. Resnick LM, Gupta RK, Laragh JH. Intracellular free magnesium in erythrocytes of essential hypertension: Relation to blood pressure and serum divalent cations. Proc Natl Acad Sci U S A. 1984;81(20 I):6511–5.

13. Resnick LM, Bardicef O, Altura BT, Alderman MH, Altura BM. Serum ionized magnesium: relation to blood pressure and racial factors. Am J Hypertens. 1997;10(12 Pt 1):1420–4.

14. Ma J, Folsom AR, Melnick SL, Eckfeldt JH, Sharrett AR, Nabulsi AA, et al. Associations of serum and dietary magnesium with cardiovascular disease, hypertension, diabetes, insulin, and carotid arterial wall thickness: The aric study. J Clin Epidemiol. 1995;48(7):927–40.

15. Touyz RM, Milne FJ, Seftel HC, Reinach SG. Magnesium, calcium, sodium and potassium status in normotensive and hypertensive Johannesburg residents. South African Med J. 1987;72(6):377–81.

16. Abbasi I ur R, Salim-ul-Haque, Kausar MW, Karira KA, Zubari NA. Correlation of divalent Cat ions (Ca++, Mg++) and Serum Renin in patients of essential hypertension. J Pak Med Assoc. 2012;62(2):134–8.

17. Houston MC, Harper KJ. Potassium, magnesium, and calcium: their role in both the cause and treatment of hypertension. Vol. 10, Journal of clinical hypertension (Greenwich, Conn.). J Clin Hypertens (Greenwich); 2008. p. 3–11.
18. Houston M. The role of magnesium in hypertension and cardiovascular disease. J Clin Hypertens. 2011;13(11):843–7.

19. Khan AM, Sullivan L, McCabe E, Levy D, Vasan RS, Wang TJ. Lack of association between serum magnesium and the risks of hypertension and cardiovascular disease. Am Heart J [Internet]. 2010;160(4):715–20. Available from: http://dx.doi.org/10.1016/j.ahj.2010.06.036

20. Peacock JM, Folsom AR, Arnett DK, Eckfeldt JH, Szklo M. Relationship of serum and dietary magnesium to incident hypertension: The Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol. 1999;9(3):159–65.

21. Guerrero-Romero F, Rodríguez-Morán M, Hernández-Ronquillo G, Gómez-Díaz R, Pizano-Zarate ML, Wacher NH, et al. Low Serum Magnesium Levels and Its Association with High Blood Pressure in Children. J Pediatr. 2016;168:93–98.e1.

22. Han H, Fang X, Wei X, Liu Y, Jin Z, Chen Q, et al. Dose-response relationship between dietary magnesium intake, serum magnesium concentration and risk of hypertension: A systematic review and meta-analysis of prospective cohort studies. Nutr J. 2017;16(1):1–12.

23. Joosten MM, Gansevoort RT, Mukamal KJ, Kootstra-Ros JE, Feskens EJM, Geleijnse JM, et al. Urinary magnesium excretion and risk of hypertension: the prevention of renal and vascular end-stage disease study. Hypertension. 2013;61(6):1161–7.

24. Petersen B, Schroll M, Christiansen C, Transbol I. Serum and Erythrocyte Magnesium in Normal Elderly Danish People: Relationship to Blood Pressure and Serum Lipids. Acta Med Scand. 1977;201(1–6):31–4.

25. Rinner MD, Spliet-van Laar L, Kromhout D. Serum sodium, potassium, calcium and magnesium and blood pressure in a Dutch population. J Hypertens [Internet]. 1989 [cited 2020 Apr 11];7(12):977–81. Available from: https://pubmed.ncbi.nlm.nih.gov/2628498/

26. Guerrero-Romero F, Rodríguez-Morán M. The effect of lowering blood pressure by magnesium
supplementation in diabetic hypertensive adults with low serum magnesium levels: A
randomized, double-blind, placebo-controlled clinical trial. J Hum Hypertens. 2009;23(4):245–51.

27. Sanjuliani AF, De Abreu Fagundes VG, Francischetti EA. Effects of magnesium on blood pressure
and intracellular ion levels of Brazilian hypertensive patients. Int J Cardiol. 1996;56(2):177–83.

28. Kawano Y, Matsuoka H, Takishita S, Omae T. Effects of magnesium supplementation in
hypertensive patients: Assessment by office, home, and ambulatory blood pressures.
Hypertension. 1998;32(2):260–5.

29. Kass L, Weekes J, Carpenter L. Effect of magnesium supplementation on blood pressure: A meta-
analysis. Eur J Clin Nutr. 2012;66(4):411–8.

30. Zhang X, Li Y, Del Gobbo LC, Rosanoff A, Wang J, Zhang W, et al. Effects of Magnesium
Supplementation on Blood Pressure: A Meta-Analysis of Randomized Double-Blind Placebo-
Controlled Trials. Hypertension. 2016;68(2):324–33.

31. Jee SHA, Miller ER, Guallar E, Singh VK, Appel LJ, Klag MJ. The effect of magnesium
supplementation on blood pressure: A meta-analysis of randomized clinical trials. Am J
Hypertens. 2002;15(8):691–6.

32. Rosanoff A, Plesset MR. Oral magnesium supplements decrease high blood pressure (SBP >
155mmHg) in hypertensive subjects on anti-hypertensive medications: A targeted meta-analysis.
Magnes Res. 2013;26(3):93–9.

33. Dickinson HO, Nicolson D, Campbell F, Beyer FR, Mason J. Potassium supplementation for the
management of primary hypertension in adults. Cochrane Database Syst Rev. 2006;(1).

34. Rogiers P, Vermeier W, Kesteloot H, Stroobandt R. Effect of the infusion of magnesium sulfate
during atrial pacing on ECG intervals, serum electrolytes, and blood pressure. Am Heart J.
1989;117(6):1278–83.

35. Jorde R, Sundsfjord J, Fitzgerald P, Bønaa KH. Serum calcium and cardiovascular risk factors and
diseases: The Tromso Study. Hypertension. 1999;34(3):484–90.

36. Kesteloot H, Joossens J V. Relationship of serum sodium, potassium, calcium, and phosphorus with blood pressure. Belgian Interuniversity Research on Nutrition and Health. Hypertension. 1988;12(6):589–93.

37. Lind L, Jakobsson S, Lithell H, Wengle B, Ljunghall S. Relation of serum calcium concentration to metabolic risk factors for cardiovascular disease. Br Med J. 1988;297(6654):960–3.

38. Schutte R, Huisman HW, Schutte AE, Malan NT, Van Rooyen JM, Fourie CMT, et al. Serum calcium revisited: Associations with 24-h ambulatory blood pressure and cardiovascular reactivity in Africans. Hypertens Res. 2010;33(7):688–94.

39. Staessen J, Sartor F, Roels H, Bulpitt CJ, Claeys F, Ducoffre G, et al. The association between blood pressure, calcium and other divalent cations: A population study. J Hum Hypertens. 1991;5(6):485–94.

40. Goto A, Yamada K, Nagoshi H, Ishiyama A, Minami M, Uehara Y, et al. Relation of 24-h ambulatory blood pressure with plasma potassium in essential hypertension. Am J Hypertens. 1997;10(3):337–40.

41. Pikilidou MI, Lasaridis AN, Sarafidis PA, Tziolas IM, Zebekakis PE, Dombros N V., et al. Blood pressure and serum potassium levels in hypertensive patients receiving or not receiving antihypertensive treatment. Clin Exp Hypertens. 2007;29(8):563–73.

42. Bulpitt CJ, Shipley MJ, Semmence A. Blood pressure and plasma sodium and potassium. Clin Sci. 1981;61(Suppl.7):85–7.